… The frequency of resistance to β-lactams among nosocomial isolates has been increasing
due to extended-spectrum β-lactamase (ESBL)-producing enteric bacilli. Although clinical …

… β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum
β-lactamase-… Simply select your manager software from the list below and click …

The spread of extended-spectrum β-lactamase (ESBL) genes in Enterobacteriaceae such
as Escherichia coli or Klebsiella spp is a major challenge to modern medical practice. …

… Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamases …
the amino acid configuration around the active site of these β-lactamases. This extends the …

The spread of extended-spectrum β-lactamases (ESBLs) in nosocomial and community-acquired
enterobacteria is an important challenge for clinicians as the therapeutic options for …

… Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum b-lactamases:
report from the ARREST Program. Antimicrob Agents Chemother 2003; 47:1643–6. …

Full article: Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing
Enterobacteriaceae to slow the emergence of carbapenem-resistant …

… Prevalence and significance of a negative extended-spectrum β-lactamase (ESBL) … SENTRY
Asia–Pacific surveillance program. J Clin Microbiol 2007;45:1478–82. Epub 7 March 2007. …

… β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum
β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. …

… 1a and 1b that are involved in cell lysis, PBP2, the inhibition of which results in a cessation
of cell division and the formation of spherical cells, and PBP3 for which inhibition arrests cell …